Private practice with Dr Seth Bilazarian

View all posts »

Radial didn't beat its rival

Apr 4, 2011 16:00 EDT


Surprising results from the RIVAL trial will stir the debate on catheter access sites. While the proponents of the femoral approach may feel vindicated, there are important circumstances—such as STEMI—in which radial shows advantageous results. Will RIVAL change your approach?

See:

Radial RIVALs femoral access for invasive ACS treatment, but doesn't beat it

RAPTOR: Femoral to radial access for PCI

From femoral to radial access for PCI: Practical tips and observations for the community based interventional practitioner

Cardiac catheterization access sites: An international perspective








Your comments
Radial didn't beat its rival
# 1 of 1
April 4, 2011 08:58 (EDT)
Mehrdad Saririan
Seth, well said, and very fair. Didn't know you were a radial enthusiast. Hope I had something to do with that.

You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

About Dr Seth Bilazarian
Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.

Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.

Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
About this blog
My intent is to create a forum for dialogue on issues pertinent to private practice cardiology around topics such as:

  • Integration of new data and guidelines on inpatient and outpatient practice in clinical and interventional cardiology
  • Practice approaches to the extra clinical issues in dealing with managed care insurers
  • Strategies for navigating the restrictions of pharmacy benefits managers (PBMs) on pharmacologic therapies for our patients
  • Experiences with restrictions on testing and imaging
The video blog (VLOG) will provide an opportunity to share broadly different approaches to the common conundrums we face in caring for patients. My hope is that this forum will provide useful data points for practice outside of tertiary and academic centers and a look inside community hospitals and physician?s practice patterns in the office, starting with mine.